References
- Brubaker RF, Ingram CJ, Schoff EO, et al. Comparison of efficacy of betaxolol-brinzolamide and timolol-dorzolamide as suppressors of aqueous humor flow in human subjects. Ophthalmology 2000;107:283–7
- DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol 2000;44:S119–S129
- Silver LH, and The Brinzolamide Primary Therapy Study Group. Clinical efficacy and safety of brinzolamide (Azopt®), a new topical carbonic anhydrase inhibitor for primary open- angle glaucoma and ocular hypertension. Am J Ophthalmol 1998:126:400–8
- March WF. The long-term safety and efficacy of brinzolamide 1. 0% (Azopt®) in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2000;129: 136–43
- Sall K, and The Brinzolamide Primary Therapy Study Group. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt®) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Surv Ophthalmol 2000;44: S155–S162
- Michaud JE, Friren B. The International Brinzolamide Adjunctive Study Group: comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:235–43
- Shin D, and The Brinzolamide Primary Therapy Study Group. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt®) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol 2000;44:S163–S168
- Kitazawa Y, Mishima H, Abe H, et al. Phase II dose-response study of ALO4862 (Azopt®) ophthalmic suspension in primary open-angle glaucoma or ocular hypertension. Folia Ophthalmol Jpn 2003;54:65–73
- Kitazawa Y, Azuma I, Iwata K, et al. Dorzolamide, a topical carbonic anhydrase inhibitor: a two-week dose-response study in patients with glaucoma or ocular hypertension. J Glaucoma 1994;3:275–9
- Kitazawa Y. Phase III comparative study of MK-506 ophthalmic solution in primary open-angle glaucoma and ocular hypertension. Folia Ophthalmol Jpn 1994;45:1023–33
- Kitazawa Y, Araie M, Kuwayama Y. Additive effect of MK- 507 in combination with p-blocker in patients with primary open-angle glaucoma and ocular hypertension. Atarashii Ganka 1994;11: 1419–26
- O'Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002;133:836–7
- Lass JH, Eriksson GL, Osterling L, et al. Comparison of corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked randomized, one-year study. Ophthalmology 2001;108:264–71
- Aoyama Y, Motoki M, Hashimoto M. Effects of various antiglaucoma eyedrops on human corneal epithelial cells. Nippon Ganka Gakkai Zasshi 2004;108:75–83
- Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival change caused by commonly used glaucoma medications. Cornea 2004;23:490–6
- Konowal A, Morrison JC, Brown SVL, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999;127:403–6
- Nelson WL, Fraunfelder FT, Sills JM, et al. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985. Am J Ophthalmol 1996;102:606–12